07:00 , May 2, 2016 |  BC Week In Review  |  Company News

Aviragen, HealthCare Royalty Partners deal

Aviragen sold an undisclosed portion of its Inavir laninamivir octanoate royalty rights to HealthCare Royalty Partners for $20 million. Aviragen said it receives about $4.5 million annually from Inavir royalties. Daiichi Sankyo Co. Ltd. (Tokyo:4568,...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Clinical News

Civacir: Phase III started

Biotest began the open-label, North American Phase III Study 988 to evaluate 200 and 300 mg/kg Civacir in up to 90 patients. Patients will receive Civacir starting on the day of liver transplant, but prior...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

Inavir laninamivir regulatory update

Daiichi submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) to expand the label for Inavir laninamivir dry powder inhaler to include the prevention of influenza infection. The second-generation, long-acting neuraminidase...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Company News

Biota, Nabi deal

The partners completed their merger. Prior to the completion, Nabi implemented a one-for-six reverse stock split. The company then changed its name to Biota Pharmaceuticals Inc. and began trading on NASDAQ on Nov. 9 under...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Company News

Biota, Nabi deal

Nabi and Biota set the exchange ratio in the companies' proposed merger via a stock deal. Nabi will acquire all of Biota Holdings' shares at a rate of about 0.125 new Nabi shares for one...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

NicVax: Preliminary Phase II data

Preliminary data from a double-blind, Dutch Phase II trial in 558 patients showed that NicVax plus Chantix varenicline missed the primary endpoint of improving abstinence rate at 12 months as measured from week 9 through...
07:00 , Oct 1, 2012 |  BC Week In Review  |  Company News

Nabi infectious, neurology news

Nabi adjourned a special shareholders meeting, during which shareholders were to vote on the proposed merger of Nabi and Biota Holdings Ltd. (ASX:BTA, Notting Hill, Australia), due to an absence of quorum. The meeting will...
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Company News

Biota, Nabi deal

The companies amended an April agreement to merge in a stock deal to address Biota's share price decline since the deal was first announced. Nabi will now contribute $27 million in cash to the combined...
07:00 , Aug 27, 2012 |  BC Week In Review  |  Clinical News

Inavir laninamivir: Phase III data

A double-blind, Japanese Phase III trial in >1,500 healthy family members of a patient with confirmed influenza infection A or B infection showed that both dose regimens of Inavir met the primary endpoint of reducing...